Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

Lung cancer is the leading cause of cancer deaths worldwide. Expression of the p53 tumor suppressor protein is frequently altered in tobacco-associated lung cancers. We studied chemopreventive effects of p53-modulating agents, namely, CP-31398 and Prima-1, on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung adenoma and adenocarcinoma formation in female A/J mice. Seven-week-old mice were treated with a single dose of NNK (10 µmol/mouse) by intraperitoneal injection and, 3 weeks later, were randomized to mice fed a control diet or experimental diets containing 50 or 100 ppm CP-31398 or 150 or 300 ppm Prima-1 for either 17 weeks (10 mice/group) or 34 weeks (15 mice/group) to assess the efficacy against lung adenoma and adenocarcinoma. Dietary feeding of 50 or 100 ppm CP-31398 significantly suppressed (P < .0001) lung adenocarcinoma by 64% and 73%, respectively, after 17 weeks and by 47% and 56%, respectively, after 34 weeks. Similarly, 150 or 300 ppm Prima-1 significantly suppressed (P < .0001) lung adenocarcinoma formation by 56% and 62%, respectively, after 17 weeks and 39% and 56%, respectively, after 34 weeks. Importantly, these results suggest that both p53 modulators cause a delay in the progression of adenoma to adenocarcinoma. Immunohistochemical analysis of lung tumors from mice exposed to p53-modulating agents showed a significantly reduced tumor cell proliferation and increased accumulation of wild-type p53 in the nucleus. An increase in p21- and apoptotic-positive cells was also observed in lung tumors of mice exposed to p53-modulating agents. These results support a chemopreventive role of p53-modulating agents in tobacco carcinogen-induced lung adenocarcinoma formation.

[1]  L. Kopelovich,et al.  p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice. , 2013, Neoplasia.

[2]  I. Kapetanovic,et al.  Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats , 2012, Cancer Chemotherapy and Pharmacology.

[3]  Galina Selivanova,et al.  Therapeutic targeting of p53 by small molecules. , 2010, Seminars in cancer biology.

[4]  V. Steele,et al.  Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. , 2009, Cancer research.

[5]  L. Kopelovich,et al.  Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. , 2008, Cancer research.

[6]  David R Bickers,et al.  CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. , 2007, The Journal of clinical investigation.

[7]  J. Roth.  Adenovirus p53 gene therapy , 2006, Expert opinion on biological therapy.

[8]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[9]  S. Hecht,et al.  Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. , 2005, Carcinogenesis.

[10]  P. Brandt-Rauf,et al.  Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway , 2005, Molecular Cancer Therapeutics.

[11]  M. You,et al.  Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf , 2005, Oncogene.

[12]  R. Cardiff,et al.  Classification of Proliferative Pulmonary Lesions of the Mouse , 2004, Cancer Research.

[13]  C. R. Herzog,et al.  Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. , 2003, Cancer research.

[14]  W. El-Deiry,et al.  Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.

[15]  S. De Flora,et al.  Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. , 2003, Cancer research.

[16]  M. Kastan,et al.  Parc-ing p53 in the Cytoplasm , 2003, Cell.

[17]  Galina Selivanova,et al.  Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. , 2002, Carcinogenesis.

[18]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[19]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[20]  A. Malkinson.  Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. , 2001, Lung cancer.

[21]  S. Lippman,et al.  Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  F. Fitzpatrick,et al.  Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Lane,et al.  Activation of p53 in cervical carcinoma cells by small molecules. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Pershagen,et al.  p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. , 2000, Cancer research.

[25]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[26]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[27]  S. Jackson,et al.  Regulation of p53 in response to DNA damage , 1999, Oncogene.

[28]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[29]  J. Barrett,et al.  Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[30]  G. Stoner.  Introduction to mouse lung tumorigenesis. , 1998, Experimental lung research.

[31]  M L Agarwal,et al.  The p53 Network* , 1998, The Journal of Biological Chemistry.

[32]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[33]  V. Steele,et al.  K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. , 1995, Carcinogenesis.

[34]  C. Willett,et al.  Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone with or without hyperoxia. , 1995, The American journal of pathology.

[35]  U. Moll,et al.  Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Hecht,et al.  Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. , 1994, Carcinogenesis.

[37]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[38]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[39]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[40]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[41]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[42]  T Takahashi,et al.  Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. , 1992, Cancer research.

[43]  A. Malkinson.  Molecular comparison of human and mouse pulmonary adenocarcinomas. , 1998, Experimental lung research.

[44]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.